Table 1 Preoperative data of the studied groups
Variables | HF group (n = 49) | CE group (n = 50) | p | |
|---|---|---|---|---|
Age (years), mean ± SD | 49.51 ± 11.3 | 48.1 ± 11.1 | 0.53 | |
Females, n (%) | 48 (98) | 48 (96) | 0.51 | |
BMI (kg/m2), mean ± SD | 30.65 ± 5.4 | 31 ± 6.5 | 0.78 | |
Smoking, n (%) | 7 (14.3) | 7 (14) | 0.96 | |
Family history, n (%) | 2 (4.1) | 2 (4) | 0.98 | |
Comorbidities, n (%) | DM | 13 (26.5) | 12 (14) | 0.77 |
HTN | 13 (26.5) | 12 (14) | 0.77 | |
Others | 15 (30.6) | 21 (42) | 0.24 | |
Histological type, n (%) | Invasive duct carcinoma | 41 (83.7) | 42 (84) | 0.32 |
DCIS | 4 (8.2) | 7 (14) | ||
Invasive lobular carcinoma | 1 (2) | 0 | ||
Invasive micropapillary carcinoma | 2 (4.1) | 0 | ||
Lobular carcinoma | 1 (2) | 0 | ||
Medullary BC | 0 | 1 (2) | ||
Receptors status, n (%) | ER positive | 32 (65.3) | 37 (74) | 0.27 |
PR positive | 30 (61.2) | 31 (62) | 0.32 | |
Her2 positive | 18 (36.7) | 20 (40) | 0.33 | |
Pre-CTH tumor size (cm), mean ± SD | 3.3 ± 0.6 | 3.2 ± 0.57 | 0.39 | |
Post-CTH tumor size (cm), mean ± SD | 1.6 ± 0.6 | 1.5 ± 0.58 | 0.13 | |
Clinical nodes, n (%) | 1 | 17 (34.7) | 31 (62) | 0.023 |
2 | 15 (30.6) | 10 (20) | ||
3 | 17 (34.7) | 9 (18) | ||
TNM stage, n (%) | I | 3 (6.1) | 3 (6) | 0.15 |
II | 22 (44.9) | 28 (56) | ||
III | 29 (59.1) | 19 (38) | ||
Type of CTH, n (%) | AC + TH | 6 (12.3) | 13 (26) | 0.17 |
AC + T | 43 (87.7) | 37 (74) | ||
No. of cycles | 4 cycles | 1 (2) | 1 (2) | 0.34 |
6 cycles | 48 (98) | 47 (94) | ||
8 cycles | 0 | 2 (4) | ||
Radiological response | CR | 5 (10.2) | 5 (10) | 0.72 |
PR | 38 (77.6) | 39 (78) | ||
SD | 4 (8.2) | 2 (4) | ||
DP | 2 (4.1) | 4 (8) | ||